Cite
HARVARD Citation
Reifsnider, O. et al. (2021). Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes, obesity & metabolism. 23 (3), pp. 791-799. [Online].